28 January 2016  
EMA/CHMP/18049/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Amlodipine-Valsartan Mylan 
amlodipine / valsartan 
On 28 January 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Amlodipine-
Valsartan Mylan, intended for the treatment of essential hypertension. The applicant for this medicinal 
product is MYLAN S.A.S. 
Amlodipine-Valsartan Mylan will be available as 5 mg / 160 mg, 5 mg / 80 mg and 10 mg / 160 mg Film-
coated tablet. The active substances of Amlodipine-Valsartan Mylan are amlodipine / valsartan, an agent 
acting on the renin-angiotensin system and calcium channel blockers. The ATC code is C09DB01 
angiotensin II antagonists, combinations. 
Amlodipine-Valsartan Mylan is a generic of Exforge, which has been authorised in the EU since 17 Jan 
2007. Studies have demonstrated the satisfactory quality of Amlodipine-Valsartan Mylan, and its 
bioequivalence to the reference product Exforge. A question and answer document on generic medicines 
can be found here. 
The full indication is: "Treatment of essential hypertension.Amlodipine/Valsartan Mylan is indicated in 
adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy. 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
 
  
 
 
 
  
                                                
